Investor Atlas Venture Fund IX, L.P.
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Atlas Venture Fund IX, L.P. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2023-01-31 13G/A SURF / Surface Oncology Inc 2,945,453 2,945,453
2022-01-25 13G/A COGT / Cogent Biosciences, Inc. 916,196 916,196
2022-01-25 13G/A SURF / Surface Oncology Inc 2,945,453 2,945,453
2022-01-25 13G/A SPRO / Spero Therapeutics, Inc. 1,376,968 1,376,968
2021-02-02 13G/A SPRO / Spero Therapeutics, Inc. 1,376,968
2021-02-02 13G/A SURF / Surface Oncology Inc 4,654,453 2,945,453
2021-02-02 13G/A COGT / Cogent Biosciences, Inc. 3,361,535 916,196
2020-12-28 13D SKLZ / Skillz Inc. 23,284,403
2020-02-04 13G/A SPRO / Spero Therapeutics, Inc. 1,376,968
2020-02-04 13G/A SURF / Surface Oncology Inc 4,654,453 4,654,453
2020-02-04 13G/A COGT / Cogent Biosciences, Inc. 3,361,535 3,361,535
2019-02-08 13G/A SPRO / Spero Therapeutics, Inc. 1,376,968
2019-02-08 13G/A NTLA / Intellia Therapeutics, Inc. 3,579,788 1,615,321
2019-02-08 13G SURF / Surface Oncology Inc 4,654,453
2019-02-08 13G COGT / Cogent Biosciences, Inc. 3,361,535
2018-02-12 13G/A NTLA / Intellia Therapeutics, Inc. 3,579,788 3,579,788
2018-02-09 13G/A NTLA / Intellia Therapeutics, Inc. 4,429,788 3,579,788
2017-09-29 13D SYBX / Synlogic, Inc. 2,651,963
2017-02-09 13G NTLA / Intellia Therapeutics, Inc. 4,429,788